Equities research analysts expect Loxo Oncology, Inc. (NASDAQ:LOXO) to report ($1.05) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have provided estimates for Loxo Oncology’s earnings. The lowest EPS estimate is ($1.07) and the highest is ($1.03). Loxo Oncology reported earnings of ($0.82) per share during the same quarter last year, which would suggest a negative year over year growth rate of 28%. The business is expected to report its next earnings results on Wednesday, November 1st.

On average, analysts expect that Loxo Oncology will report full-year earnings of ($4.33) per share for the current financial year, with EPS estimates ranging from ($4.49) to ($4.17). For the next financial year, analysts forecast that the firm will post earnings of ($4.10) per share, with EPS estimates ranging from ($4.74) to ($3.13). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that cover Loxo Oncology.

Loxo Oncology (NASDAQ:LOXO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.15). During the same quarter in the previous year, the company earned ($0.77) EPS.

A number of analysts have recently weighed in on LOXO shares. JMP Securities downgraded shares of Loxo Oncology from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $83.12 to $17.14 in a research report on Tuesday, August 29th. They noted that the move was a valuation call. Morgan Stanley reissued an “overweight” rating and set a $103.00 price objective (up from $95.00) on shares of Loxo Oncology in a research report on Friday, October 6th. BTIG Research reissued a “buy” rating and set a $75.00 price objective on shares of Loxo Oncology in a research report on Thursday, August 3rd. BidaskClub downgraded shares of Loxo Oncology from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $71.00 price objective on shares of Loxo Oncology in a research report on Thursday, August 3rd. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $80.02.

In related news, insider Naarden Jacob Van sold 1,541 shares of the stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $73.73, for a total transaction of $113,617.93. Following the sale, the insider now directly owns 1,541 shares of the company’s stock, valued at approximately $113,617.93. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Keith T. Flaherty sold 7,250 shares of the stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $72.26, for a total transaction of $523,885.00. Following the sale, the director now directly owns 20,432 shares in the company, valued at $1,476,416.32. The disclosure for this sale can be found here. Insiders have sold a total of 89,896 shares of company stock worth $7,315,562 over the last three months. 44.40% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of LOXO. Wells Fargo & Company MN lifted its stake in Loxo Oncology by 33.3% during the 1st quarter. Wells Fargo & Company MN now owns 15,503 shares of the biopharmaceutical company’s stock valued at $653,000 after acquiring an additional 3,875 shares during the period. Bank of New York Mellon Corp lifted its stake in Loxo Oncology by 41.8% during the 1st quarter. Bank of New York Mellon Corp now owns 102,442 shares of the biopharmaceutical company’s stock valued at $4,310,000 after acquiring an additional 30,210 shares during the period. Swiss National Bank lifted its stake in Loxo Oncology by 53.5% during the 1st quarter. Swiss National Bank now owns 28,700 shares of the biopharmaceutical company’s stock valued at $1,208,000 after acquiring an additional 10,000 shares during the period. Parametric Portfolio Associates LLC bought a new position in Loxo Oncology during the 1st quarter valued at about $1,586,000. Finally, American International Group Inc. lifted its stake in Loxo Oncology by 27.1% during the 1st quarter. American International Group Inc. now owns 9,749 shares of the biopharmaceutical company’s stock valued at $410,000 after acquiring an additional 2,081 shares during the period.

TRADEMARK VIOLATION NOTICE: “Analysts Anticipate Loxo Oncology, Inc. (LOXO) Will Announce Earnings of -$1.05 Per Share” was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/22/analysts-anticipate-loxo-oncology-inc-loxo-will-announce-earnings-of-1-05-per-share.html.

Loxo Oncology (NASDAQ:LOXO) traded up 1.87% on Friday, hitting $86.62. 357,842 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $86.48 and a 200-day moving average price of $69.16. Loxo Oncology has a 52-week low of $17.14 and a 52-week high of $95.92. The stock’s market cap is $2.59 billion.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Get a free copy of the Zacks research report on Loxo Oncology (LOXO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.